Autolus Therapeutics (NASDAQ:AUTL) Trading 7.1% Higher - Should You Buy?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report)'s stock price traded up 7.1% during mid-day trading on Monday . The stock traded as high as $2.21 and last traded at $2.20. 1,000,925 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,565,929 shares. The stock had previously closed at $2.05.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Wells Fargo & Company cut their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Truist Financial cut their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, June 12th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics presently has a consensus rating of "Buy" and an average target price of $9.32.

Autolus Therapeutics Stock Down 0.4%

The company has a market cap of $614.78 million, a price-to-earnings ratio of -2.63 and a beta of 1.76. The company has a fifty day simple moving average of $1.71 and a two-hundred day simple moving average of $1.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The business had revenue of $8.98 million during the quarter, compared to the consensus estimate of $1.59 million. On average, research analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Institutional Trading of Autolus Therapeutics

A number of large investors have recently made changes to their positions in AUTL. Handelsbanken Fonder AB boosted its stake in shares of Autolus Therapeutics by 30.9% during the fourth quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company's stock valued at $172,000 after acquiring an additional 17,300 shares during the last quarter. Candriam S.C.A. acquired a new stake in shares of Autolus Therapeutics during the fourth quarter valued at $7,500,000. Daiwa Securities Group Inc. boosted its stake in shares of Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock valued at $56,000 after acquiring an additional 8,479 shares during the last quarter. Privium Fund Management B.V. boosted its stake in shares of Autolus Therapeutics by 24.8% during the fourth quarter. Privium Fund Management B.V. now owns 231,674 shares of the company's stock valued at $544,000 after acquiring an additional 46,035 shares during the last quarter. Finally, EntryPoint Capital LLC acquired a new stake in shares of Autolus Therapeutics during the fourth quarter valued at $450,000. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.